21. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study. (Q50327327)
Jump to navigation
Jump to search
scientific article published on 20 March 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | 21. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study. |
scientific article published on 20 March 2017 |
Statements
1 reference
21. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study (English)
Michael Sand
David Brown
Kazuyuki Nakagome
Joachim Cordes
Ronald Brenner
Gerhard Gruender
Richard Keefe
Robert Riesenberg
David Walling
Kristen Daniels
Lara Wang
Jennifer McGinniss
20 March 2017
1 reference